Metronidazol Altan

Metronidazole, the active ingredient in Metronidazol Altan, is a nitroimidazole antibiotic presented as an injectable solution for intravenous use. It treats anaerobic bacterial and protozoal infections in adults and children as prescribed by a qualified health professional.

GNH USA supplies Metronidazol Altan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metronidazol Altan is employed to manage infections caused by anaerobic microorganisms and certain protozoa.

- Intra‑abdominal infections: eliminates anaerobic bacteria and supports recovery after surgery or perforation. - Pelvic inflammatory disease: eradicates causative anaerobes and improves pelvic health. - Bacterial sepsis caused by susceptible anaerobes: provides rapid systemic antimicrobial action. - Skin and soft‑tissue infections with anaerobic involvement: reduces bacterial load and promotes wound healing. - Bone and joint infections (osteomyelitis) with anaerobic pathogens: assists in infection control and tissue repair.

Metronidazol Altan may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient metallic sensation in the mouth. - Headache: mild to moderate cephalgia. - Diarrhea: loose stools, usually self‑limiting. - Abdominal pain: cramping or discomfort. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Seizures: rare neurologic events, especially with high doses. - Peripheral neuropathy: tingling or numbness in extremities. - Stevens‑Johnson syndrome: severe skin reactions. - Anaphylaxis: acute allergic response requiring emergency care. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Severe neutropenia: marked reduction in white blood cells.

Metronidazol Altan requires careful consideration of patient‑specific factors and proper handling to ensure safety. - Renal impairment: adjust dose or monitor renal function closely. - Hepatic dysfunction: use with caution; monitor liver enzymes. - Alcohol consumption: avoid due to disulfiram‑like reaction. - Hematologic disorders: watch for neutropenia or thrombocytopenia. - Pregnancy and breastfeeding: assess risk‑benefit; limited data available. - Store at ambient temperature: keep in original container, protect from moisture and light.

Metronidazol Altan can influence or be influenced by several concomitant medicines.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, tachycardia, and hypotension. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: may raise lithium serum levels, leading to toxicity. - Carbamazepine: reduces metronidazole concentrations, diminishing efficacy.

Moderate Interactions (Monitor Closely): - Phenytoin: may lower metronidazole levels; monitor therapeutic response. - Phenobarbital: similar enzyme‑inducing effect as phenytoin. - Rifampin: decreases metronidazole exposure; adjust dose if needed. - Oral contraceptives: may reduce hormonal efficacy; advise additional contraception. - Cyclosporine: can increase cyclosporine concentrations; monitor renal function.